Inventiva (NASDAQ:IVA) PT Lowered to $14.00

Inventiva (NASDAQ:IVA) had its price target reduced by investment analysts at HC Wainwright from $22.00 to $14.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Stifel Nicolaus decreased their price target on shares of Inventiva from $25.00 to $20.00 and set a “buy” rating for the company in a report on Thursday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.50.

Inventiva Stock Up 2.8 %

NASDAQ IVA opened at $1.84 on Thursday. Inventiva has a one year low of $1.53 and a one year high of $4.75. The company has a 50-day simple moving average of $2.25 and a 200-day simple moving average of $2.97.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC bought a new stake in shares of Inventiva S.A. (NASDAQ:IVA) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.